Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Summary

The purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.

Timeline

Start

2022-12-28

Primary completion

2026-11

Completion

2027-11

Publications

• Hatoum F, Souza GR, Johnson J, Miller J, Fazili A, Pettaway CA, Campbell MT, Neubauer R, Johns A, Mizelle SR, Kim Y, Chadha J, Zhang J, Jameel G, Oschmann E, Dhillon J, Moscu A, Janeway R, Harris W, Lu X, Spiess PE, Chahoud J. Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinoma. Future Oncol. 2025 Dec;21(28):3619-3627. doi: 10.1080/14796694.2025.2577632. Epub 2025 Oct 30.

Drugs

Indications